OMCL Q1 2026 Earnings Call Summary

1Key Financial Results and Metrics

Total Revenue: $310 million, up 15% year-over-year, at the high end of guidance.

Product Revenue: $175 million, a 20% increase year-over-year.

Service Revenue: $135 million, an 8% increase year-over-year.

Non-GAAP EBITDA: $45 million, compared to $24 million a year ago.

Non-GAAP Earnings Per Share: $0.55, up from $0.26 in Q1 2025.

GAAP Earnings Per Share: $0.25, compared to a loss of $0.15 in Q1 2025.

Non-GAAP Gross Margin: 46%, improved from 42% in Q1 2025.

Cash and Cash Equivalents: $239 million, down from $387 million year-over-year, primarily due to debt repayment and stock repurchases.

Free Cash Flow: $39 million, up from $10 million in the prior year.

2Strategic Updates and Business Highlights

Omnicell is focusing on autonomous medication management, with three strategic priorities: expanding market presence, scaling recurring revenue, and advancing the OmniSphere platform.

The introduction of Omnicell Titan XT, a next-generation automated dispensing system, is aimed at enhancing operational efficiency and customer engagement.

Positive customer feedback on Titan XT's capabilities, particularly in improving workflow efficiency and inventory management.

Continued growth in Specialty Pharmacy Services and strong engagement in outpatient settings.

The company is seeing increased demand for its solutions as health systems reassess incumbent technologies.

3Forward Guidance and Outlook

Q2 2026 Revenue Guidance: Expected between $307 million and $313 million.

Full Year 2026 Revenue Guidance: Maintained at $1.215 billion to $1.255 billion.

Non-GAAP EBITDA Guidance: Increased to $153 million to $168 million.

Non-GAAP Earnings Per Share Guidance: Increased to $1.80 to $2.00.

The company anticipates product bookings to be weighted towards the second half of 2026 due to capital approval cycles.

4Bad News, Challenges, or Points of Concern

The retail pharmacy segment continues to face challenges, although there are signs of stabilization.

Capital approval cycles: for health systems remain lengthy, which may delay revenue recognition.

The installed base for the XT series is younger than anticipated, potentially impacting the pace of upgrades to Titan XT.

Tariff-related costs are expected to impact the P&L by approximately $12 million in 2026.

5Notable Q&A Insights

Discussions around competitive conversions indicate a shift in customer interest from existing solutions to Titan XT, with some customers reevaluating their upgrade paths.

There is a growing pipeline of opportunities, particularly in light of competitors facing challenges, including a Class II FDA recall.

The company is exploring leasing and financing options to accommodate customer cash flow needs, which is seen as beneficial for deal-making.

While there is a positive outlook on competitive dynamics, there is no significant increase in sole-source agreements noted at this time. Overall, Omnicell's Q1 2026 results reflect strong execution and a positive outlook, though challenges remain in the retail segment and capital approval processes. The company is well-positioned to leverage its new product offerings to drive growth in the coming quarters.